Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(43%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_4
2
29%
Ph phase_3
3
43%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 33 (42.9%)
Phase 42 (28.6%)

Trials by Status

withdrawn114%
completed343%
recruiting343%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

NCT07298044
recruitingphase_3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895
completedphase_1

Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

NCT04958135
recruitingphase_4

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

NCT07306949
withdrawnphase_3

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

NCT04882735
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07298044Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Recruiting
NCT06563895Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Recruiting
NCT04958135Phase 1

Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

Completed
NCT07306949Phase 4

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

Recruiting
NCT04882735Phase 3

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Withdrawn
NCT04769479Phase 1

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

Completed
NCT03860935Phase 3

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7